Myriad Genetics Inc. (MYGN)
10.00
-0.01 (-0.10%)
At close: Mar 24, 2025, 3:59 PM
10.07
0.68%
After-hours: Mar 24, 2025, 07:46 PM EDT
-0.10% (1D)
| Bid | 9.61 |
| Market Cap | 913.09M |
| Revenue (ttm) | 827.31M |
| Net Income (ttm) | -116.52M |
| EPS (ttm) | -1.41 |
| PE Ratio (ttm) | -7.09 |
| Forward PE | 198.89 |
| Analyst | Hold |
| Ask | 10.53 |
| Volume | 461,643 |
| Avg. Volume (20D) | 1,103,906 |
| Open | 10.12 |
| Previous Close | 10.01 |
| Day's Range | 9.90 - 10.25 |
| 52-Week Range | 9.36 - 29.30 |
| Beta | 1.79 |
About MYGN
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Oct 6, 1995
Employees 2,700
Stock Exchange NASDAQ
Ticker Symbol MYGN
Website https://myriad.com
Analyst Forecast
According to 14 analyst ratings, the average rating for MYGN stock is "Hold." The 12-month stock price forecast is $20, which is an increase of 100.00% from the latest price.
Stock ForecastsNext Earnings Release
Myriad Genetics Inc. is scheduled to release its earnings on May 6, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+1.56%
Myriad Genetics shares are trading higher after Pi...
Unlock content with
Pro Subscription
3 weeks ago
-14.8%
Myriad Genetics shares are trading lower following a Q4 revenue miss and FY25 revenue guidance below estimates. The stock may also be trading on weakness after it announced it will face cost restructuring following UnitedHealthcare's decision to end Genesight coverage. Additionally, UBS and Raymond James cut their respective price targets on the stock.
